Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | TEK | Q02763 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.47 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 4/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690494 | 0.88 | EGFR (0.56) | SCN9ANPC1MEN1KMT2ARAB9A | |
| SCHEMBL12487147 | 0.85 | NPC1 (0.64) | SCN9ANPC1MEN1KMT2ARAB9A | |
| SCHEMBL857502 | 0.85 | NPC1 (0.63) | NPC1MEN1KMT2ARAB9AEGFR | |
| Hydrochloric Acid SCHEMBL2176643 | 0.84 | NPC1 (0.61) | NPC1MEN1KMT2ARAB9AEGFR | |
| SCHEMBL30046349 | 0.83 | SCN9A (0.76) | SCN9ANPC1MEN1KMT2ARAB9A | |
| SCHEMBL3487003 | 0.82 | MEN1 (0.61) | SCN9ANPC1MEN1KMT2ARAB9A | |
| SCHEMBL856014 | 0.81 | MEN1 (0.78) | SCN9ANPC1MEN1KMT2ARAB9A | |
| SCHEMBL3487000 | 0.81 | MEN1 (0.64) | SCN9ANPC1MEN1KMT2ARAB9A | |
| SCHEMBL2283204 | 0.79 | NPC1 (0.68) | SCN9ANPC1MEN1KMT2AKDR | |
| SCHEMBL2179743 | 0.78 | MEN1 (0.61) | SCN9ANPC1MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519501-B1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES FOR THE PRODUCTION OF CARDIOMYOCYTE-LIKE CELLS | UNIV WIEN TECH (AT) | 2015-04-22 | — | — | EP | disclosed |
| EP-2519501-B1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES FOR THE PRODUCTION OF CARDIOMYOCYTE-LIKE CELLS | UNIV WIEN TECH (AT) | 2015-04-22 | — | — | EP | disclosed |
| US-8986994-B2 | Substituted pyridines and pyrimidines | TECHNISCHE UNIVERSITAET WIEN (AT) | 2015-03-24 | — | — | US | disclosed |
| US-8986994-B2 | Substituted pyridines and pyrimidines | TECHNISCHE UNIVERSITAET WIEN (AT) | 2015-03-24 | — | — | US | disclosed |
| US-8986994-B2 | Substituted pyridines and pyrimidines | TECHNISCHE UNIVERSITAET WIEN (AT) | 2015-03-24 | — | — | US | disclosed |
| US-20120294835-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | MEDIZINISCHE UNIVERSITAET WIEN (AT) | 2012-11-22 | — | — | US | disclosed |
| US-20120294835-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | MEDIZINISCHE UNIVERSITAET WIEN (AT) | 2012-11-22 | — | — | US | disclosed |
| US-20120294835-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | MEDIZINISCHE UNIVERSITAET WIEN (AT) | 2012-11-22 | — | — | US | disclosed |
| EP-2519501-A2 | SUBSTITUTED PYRIDINES AND PYRIMIDINES FOR THE PRODUCTION OF CARDIOMYOCYTE-LIKE CELLS | Technische Universität Wien (AT) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011079343-A2 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | TECHNISCHE UNIVERSITAET WIEN (AT) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011079343-A2 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | TECHNISCHE UNIVERSITAET WIEN (AT) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120294835-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | TNNI3, TNNT2, PROX1 | SCN9A 856/4885NPC1 4262/4885MEN1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.